Use of HeberFERON® in an HIV/AIDS patient with basal cell carcinoma
Abstract
Introduction: basal cell carcinoma is a malignant neoplasm of the lining epithelium. Its appearance is closely linked to exposure to sunlight. Although it constitutes 60 % of skin tumors, it is considered a malignant neoplasm with a good prognosis.
Objective: to present the case of an HIV/AIDS patient with facial basal cell carcinoma treated with HeberFERON®.
Case presentation: a 70-year-old white male patient who attended the maxillofacial surgery consultation in February 2016 to remove a three-year-old lesion on the nose. He had a history of high blood pressure, had been an HIV carrier for 16 years and had undergone surgery on five occasions for presenting basal cell carcinomas of the face. He refused surgical treatment due to complications from previous operations. For this reason, treatment with HeberFERON® was suggested, an option that he accepted. After four years, during the consultation to verify the evolution of the disease, the patient was cured and expressed his satisfaction with the procedure.
Conclusions:with the use of HeberFERON®, complete regression of the facial basal cell carcinoma that he suffered was achieved in this patient, and the performance of a non-consensual surgical act was avoided. The treatment had excellent oncological, aesthetic and psychological results, with minimal complications. The contribution of this work lies in highlighting the option of drug treatment with HeberFERON® in those cases in which patients with basal cell carcinoma do not consent to surgical intervention, with excellent results in an immunodeficient patient.
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.
The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.
